Disclosure Quest - Search SEC Filings

Name	Type of Offering	Accepted Date
OcuTerra Therapeutics, Inc. See All Filings	D/A	2024-02-22 15:25:02 UTC
Amount To Be Raised $25,625,440 Associated Brokers / Dealers Maxim Group LLC CIK Number 0001641226 Filed Document 0001641226-24-000001 Exclusions or Exemptions 506b Accepted Date 2024-02-22 15:25:02 UTC Type of Offering D/A Industry Other Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Equity
OcuTerra Therapeutics, Inc. See All Filings	D	2023-12-22 11:22:12 UTC
Amount To Be Raised $30,000,000 Associated Brokers / Dealers Maxim Group LLC CIK Number 0001641226 Filed Document 0001641226-23-000001 Exclusions or Exemptions 506b Accepted Date 2023-12-22 11:22:12 UTC Type of Offering D Industry Other Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Equity
OcuTerra Therapeutics, Inc. See All Filings	D/A	2021-08-24 16:27:41 UTC
Amount To Be Raised $50,000,000 Associated Brokers / Dealers Maxim Group LLC CIK Number 0001641226 Filed Document 0001641226-21-000003 Exclusions or Exemptions 506b Accepted Date 2021-08-24 16:27:41 UTC Type of Offering D/A Industry Pharmaceuticals Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Equity
SciFluor Life Sciences, Inc. See All Filings	D	2021-05-11 16:35:59 UTC
Amount To Be Raised $40,000,000 Associated Brokers / Dealers Maxim Group LLC CIK Number 0001641226 Filed Document 0001641226-21-000002 Exclusions or Exemptions 506b Accepted Date 2021-05-11 16:35:59 UTC Type of Offering D Industry Pharmaceuticals Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Equity
SciFluor Life Sciences, Inc. See All Filings	D	2019-09-26 08:59:12 UTC
Amount To Be Raised $1,500,000 Associated Brokers / Dealers Maxim Group LLC CIK Number 0001641226 Filed Document 0001641226-19-000006 Exclusions or Exemptions 506b Accepted Date 2019-09-26 08:59:12 UTC Type of Offering D Industry Pharmaceuticals Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Debt